News & Updates

Luspatercept a new SoC for TD LR-MDS?

05 Jan 2024 by

The full analysis of the phase III COMMANDS trial continues to demonstrate the superiority of luspatercept over epoetin alfa for the treatment of erythropoiesis-stimulating agent (ESA)-naïve patients with transfusion-dependent lower-risk myelodysplastic syndromes (TD LR-MDS).

Luspatercept a new SoC for TD LR-MDS?

05 Jan 2024

Multiple myeloma quadruplet prolongs survival, induces deeper responses

02 Jan 2024 by

Adding subcutaneous daratumumab to the three-drug regimen containing bortezomib, lenalidomide, and dexamethasone (VRd) appears to improve outcomes for transplant-eligible patients with newly diagnosed multiple myeloma (MM), with extended disease-free periods and increased depth of response, according to the phase III PERSEUS trial.

Multiple myeloma quadruplet prolongs survival, induces deeper responses

02 Jan 2024

$Ibrutinib plus venetoclax yields survival gains in relapsed/refractory mantle cell lymphoma$

Ibrutinib plus venetoclax yields survival gains in relapsed/refractory mantle cell lymphoma

29 Dec 2023 by

In the treatment of patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), taking ibrutinib and venetoclax together prolongs survival without disease progression, according to the phase III Sympatico study.

Ibrutinib plus venetoclax yields survival gains in relapsed/refractory mantle cell lymphoma

29 Dec 2023

Sunvozertinib shows promise in pretreated NSCLC with EGFR exon 20 insertions

29 Dec 2023

The oral selective tyrosine kinase inhibitor sunvozertinib demonstrates therapeutic potential in patients with nonsmall cell lung cancer (NSCLC) with EGFR exon 20 insertions (exon20ins) who have previously received platinum-based chemotherapy, according to the results of a phase II WU-KONG6 study.

Sunvozertinib shows promise in pretreated NSCLC with EGFR exon 20 insertions

29 Dec 2023

First-line ipilimumab plus nivolumab delivers benefits in metastatic renal cell carcinoma

22 Dec 2023 by

First-line combination immuno-oncology therapy (IO) with ipilimumab and nivolumab provides beneficial effects and has an acceptable safety profile in patients with metastatic renal cell carcinoma, as shown in a Japan study presented at ESMO Asia 2023.

First-line ipilimumab plus nivolumab delivers benefits in metastatic renal cell carcinoma

22 Dec 2023

Liquid NGS helps prolong survival in patients with advanced solid tumours

22 Dec 2023 by

Patients with advanced solid tumours who have been treated according to matched targetable genomic mutation exhibit significantly longer overall survival than those who received standard-of-care (SOC) treatment, according to a Philippines study presented at ESMO Asia 2023.

Liquid NGS helps prolong survival in patients with advanced solid tumours

22 Dec 2023

Risankizumab as induction therapy induces clinical remission in UC

22 Dec 2023 by

Induction therapy with risankizumab, a monoclonal antibody neutralizing interleukin-23p19, resulted in significantly higher clinical remission rates among patients with moderate-to-severe ulcerative colitis (UC) compared with placebo, according to the INSPIRE trial presented at AIBD 2023.

Risankizumab as induction therapy induces clinical remission in UC

22 Dec 2023

Abiraterone plus prednisolone, enzalutamide a toss-up in castration-resistant prostate cancer

21 Dec 2023 by

The combination of abiraterone plus prednisolone appears to have similar efficacy and safety as enzalutamide in the treatment of patients with nonmetastatic castration-resistant prostate cancer, according to a study.

Abiraterone plus prednisolone, enzalutamide a toss-up in castration-resistant prostate cancer

21 Dec 2023

Mobocertinib only as good as platinum chemo in first-line NSCLC treatment

20 Dec 2023 by

In the first-line treatment of locally advanced or metastatic nonsmall cell lung cancer (NSCLC) patients with EGFR exon 20 insertion (ex20ins) mutations, the investigational mobocertinib is safe and efficacious but not necessarily better than platinum-based chemotherapy, according to the phase III EXCLAIM-2 trial.

Mobocertinib only as good as platinum chemo in first-line NSCLC treatment

20 Dec 2023

Add-on ribociclib continues to triumph in early breast cancer

20 Dec 2023 by

Coming on the heels of the second interim analysis, the protocol-specified final invasive disease-free survival (iDFS) analysis of the phase III NATALEE trial continues to show a highly significant iDFS benefit with the combination of the CDK 4/6 inhibitor ribociclib and a nonsteroidal aromatase inhibitor (NSAI) in individuals with HR+/HER2- early breast cancer.

Add-on ribociclib continues to triumph in early breast cancer

20 Dec 2023

News & Updates

Filter by Specialty:

Specialty:

Luspatercept a new SoC for TD LR-MDS?

Luspatercept a new SoC for TD LR-MDS?

Multiple myeloma quadruplet prolongs survival, induces deeper responses

Multiple myeloma quadruplet prolongs survival, induces deeper responses

Ibrutinib plus venetoclax yields survival gains in relapsed/refractory mantle cell lymphoma

Ibrutinib plus venetoclax yields survival gains in relapsed/refractory mantle cell lymphoma

Sunvozertinib shows promise in pretreated NSCLC with EGFR exon 20 insertions

Sunvozertinib shows promise in pretreated NSCLC with EGFR exon 20 insertions

First-line ipilimumab plus nivolumab delivers benefits in metastatic renal cell carcinoma

First-line ipilimumab plus nivolumab delivers benefits in metastatic renal cell carcinoma

Liquid NGS helps prolong survival in patients with advanced solid tumours

Liquid NGS helps prolong survival in patients with advanced solid tumours

Risankizumab as induction therapy induces clinical remission in UC

Risankizumab as induction therapy induces clinical remission in UC

Abiraterone plus prednisolone, enzalutamide a toss-up in castration-resistant prostate cancer

Abiraterone plus prednisolone, enzalutamide a toss-up in castration-resistant prostate cancer

Mobocertinib only as good as platinum chemo in first-line NSCLC treatment

Mobocertinib only as good as platinum chemo in first-line NSCLC treatment

Add-on ribociclib continues to triumph in early breast cancer

Add-on ribociclib continues to triumph in early breast cancer